| Substituting Warfarin Products: What's the Source of the Problem? | |
| | |
MedLine Citation:
|
PMID: 21666090 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Many clinicians have expressed concerns about the bioequivalence of warfarin products, and data suggest that substituting warfarin products may increase the risk of major bleeding and thromboembolic complications. Anecdotal reports and some retrospective studies have reported differences in anticoagulation control after a warfarin product substitution. But the best available evidence-prospective, randomized, blinded clinical trials-has failed to validate these observations. Indeed, interpatient and intrapatient variability in anticoagulation control observed before and after warfarin product substitution is very similar. So, while differences in product standardization, bioavailability, and bioequivalence make a convenient explanation, the problem lies elsewhere. Perhaps poor communication, fractionated systems of care, and errors are the culprits. |
| | |
Authors:
|
Stuart T Haines |
Publication Detail:
|
Type: Journal Article Date: 2011-06-10 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 45 ISSN: 1542-6270 ISO Abbreviation: Ann Pharmacother Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 807-9 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland, Baltimore, MD. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ulipristal acetate for emergency contraception.
Next Document: Methadone Toxicity Due to Smoking Cessation--A Case Report on the Drug-Drug Interaction Involving Cy...